LncRNA as potential biomarker and therapeutic target in glioma.
Xun XuYuan LiangIlgiz GareevYanchao LiangRui LiuNing WangGuang YangPublished in: Molecular biology reports (2022)
Glioma is the most frequent type of malignant tumor in the central nervous system, accounting for about 80% of primary malignant brain tumors, usually with a poor prognosis. A number of studies have been conducted on the molecular abnormalities in glioma to further understand its pathogenesis, and it has been found that lncRNAs (long non-coding RNA) play a key role in angiogenesis, tumor growth, infiltration and metastasis of glioma. Since specific lncRNAs have an aberrant expression in brain tissue, cerebrospinal fluid as well as peripheral circulation of glioma patients, they are considered to be potential biomarkers. This review focuses on the biological characteristics of lncRNA and its value as a biomarker for glioma diagnosis and prognosis. Moreover, in view of the role of lncRNAs in glioma proliferation and chemoradiotherapy resistance, we discussed the feasibility for lncRNAs as therapeutic targets. Finally, the persisting deficiencies and future prospects of using lncRNAs as clinical biomarkers and therapeutic targets were concluded.
Keyphrases
- poor prognosis
- long non coding rna
- cerebrospinal fluid
- network analysis
- end stage renal disease
- genome wide identification
- current status
- radiation therapy
- genome wide analysis
- multiple sclerosis
- white matter
- transcription factor
- patient reported outcomes
- single molecule
- brain injury
- blood brain barrier
- functional connectivity